- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00267657
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
January 10, 2017 updated by: National Institute on Drug Abuse (NIDA)
Assessment of Interactions Between IV Methamphetamine and Reserpine
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Study Overview
Detailed Description
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Study Type
Interventional
Enrollment
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- U of CA, San Francisco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 45 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Please contact site for more details
Exclusion Criteria:
- Please contact site for more details
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Craving
|
Cardiovascular
|
Subjective symptoms/Mood Effects
|
CNS norepinephrine turnover
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Study Completion
November 1, 2004
Study Registration Dates
First Submitted
December 20, 2005
First Submitted That Met QC Criteria
December 20, 2005
First Posted (ESTIMATE)
December 21, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
January 11, 2017
Last Update Submitted That Met QC Criteria
January 10, 2017
Last Verified
December 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Amphetamine-Related Disorders
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Adrenergic Uptake Inhibitors
- Reserpine
Other Study ID Numbers
- NIDA-CPU-0006-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amphetamine-Related Disorders
-
National Taiwan University HospitalUnknownMethamphetamine Dependence | Methamphetamine Abuse | Amphetamine Dependence | Amphetamine AbuseTaiwan
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); Society of Alcoholism and other AddictionsCompletedAmphetamine DependenceIceland
-
Shanghai Mental Health CenterCompletedAmphetamine AddictionChina
-
Centre hospitalier de l'Université de Montréal...Withdrawn
-
Shanghai Mental Health CenterCompleted
-
University of VirginiaAmerican Association of Chairs of Departments of PsychiatryWithdrawnAmphetamine DependenceUnited States
-
The University of New South WalesSt Vincent's Hospital, Sydney; Australian Government Department of Health and... and other collaboratorsUnknown
-
Shanghai Mental Health CenterRecruitingAmphetamine AddictionChina
-
California Pacific Medical Center Research InstituteUnknownSubstance Dependence | Amphetamine DependenceUnited States
Clinical Trials on Reserpine
-
Mayo ClinicWithdrawnPulmonary Artery HypertensionUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)National Institute on Aging (NIA)CompletedHeart Diseases | Cardiovascular Diseases | Cerebrovascular Disorders | Hypertension
-
National Heart, Lung, and Blood Institute (NHLBI)National Institute on Aging (NIA)CompletedHeart Diseases | Cardiovascular Diseases | Vascular Diseases | Hypertension
-
University of Alabama at BirminghamCompleted
-
National Institute on Drug Abuse (NIDA)Cincinnati VA Medical CenterCompletedSubstance-Related Disorders | Cocaine-Related DisordersUnited States
-
Zeng ChanghaoTerminated
-
National Heart, Lung, and Blood Institute (NHLBI)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedCardiovascular Diseases | Coronary Disease | Hypertension | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Atherosclerosis | HypercholesterolemiaUnited States, Canada
-
University of UtahBoston University; University of Pennsylvania; Northwestern University; Columbia... and other collaboratorsCompleted